what the broker likes: 1. Fast path to market. Formerly a Johnson & Johnson (J&J) developmental cancer drug, ISLA-101 has been through 48x Phase I and II clinical trials before being re-purposed - verified safe in humans by multiple regulators (including the FDA, twice) 2. Strong initial efficacy data. Promising results in human and animal studies for dengue, Zika & other viruses. 3. Very large target market. ~390m humans are infected with dengue fever alone each year (up to 50% with no symptoms) – significant revenue potential 4. Eligible for a Priority Review Voucher (PRV) for each of dengue, Zika and Chikungunya (= 3x “shots on goal”) – average sale price of a PRV ~US$100m; up to US$350m (not reflected in Island IPO valuation) 5. IPO valuation of $12.5m (pre-money) vs list peer mkt caps of:Anti-virals: Starpharma ($590m), Biotron ($57m)Re-purposed drugs: Paradigm Biopharmaceuticals ($541m), PharmAust ($32m), Race Oncology ($240m)PRV-eligible drugs: Kazia Therapeutics ($170m), Race Oncology ($240m)
ILA Price at posting:
0.0¢ Sentiment: None Disclosure: Held
